-
2
-
-
0003593229
-
Colorectal cancer
-
Vokes EE, Golomb HM (eds): 2nd edition. Berlin: Springer-Verlag
-
Kindler HL, Schilsky RL. Colorectal cancer. In Vokes EE, Golomb HM (eds): Oncologic Therapies, 2nd edition. Berlin: Springer-Verlag 2003; 425-438.
-
(2003)
Oncologic Therapies
, pp. 425-438
-
-
Kindler, H.L.1
Schilsky, R.L.2
-
3
-
-
0033874892
-
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer
-
de Gramont A, Figer A, Seymour M et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938-2947.
-
(2000)
J. Clin. Oncol.
, vol.18
, pp. 2938-2947
-
-
de Gramont, A.1
Figer, A.2
Seymour, M.3
-
4
-
-
0034727063
-
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer
-
Irinotecan Study Group
-
Saltz LB, Cox JV, Blanke C et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000; 343: 905-914.
-
(2000)
N. Engl. J. Med.
, vol.343
, pp. 905-914
-
-
Saltz, L.B.1
Cox, J.V.2
Blanke, C.3
-
5
-
-
0034712536
-
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial
-
Douillard JY, Cunningham D, Roth AD et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355: 1041-1047.
-
(2000)
Lancet
, vol.355
, pp. 1041-1047
-
-
Douillard, J.Y.1
Cunningham, D.2
Roth, A.D.3
-
7
-
-
0026762801
-
Dephosphorylation of cdc2 on threonine 161 is required for cdc2 kinase inactivation and normal anaphase
-
Lorca T, Labbe JC, Devault A et al. Dephosphorylation of cdc2 on threonine 161 is required for cdc2 kinase inactivation and normal anaphase. EMBO J 1992; 11: 2381-2390.
-
(1992)
EMBO J.
, vol.11
, pp. 2381-2390
-
-
Lorca, T.1
Labbe, J.C.2
Devault, A.3
-
9
-
-
0025936623
-
cdc2 phosphorylation is required for its interaction with cyclin
-
Ducommun B, Brambilla P, Felix MA et al. cdc2 phosphorylation is required for its interaction with cyclin. EMBO J 1991; 10: 3311-3319.
-
(1991)
EMBO J.
, vol.10
, pp. 3311-3319
-
-
Ducommun, B.1
Brambilla, P.2
Felix, M.A.3
-
10
-
-
0026027660
-
2/M transitions of the cell cycle: Identification of major phosphorylation sites
-
2/M transitions of the cell cycle: identification of major phosphorylation sites. EMBO J 1991; 10: 305-316.
-
(1991)
EMBO J.
, vol.10
, pp. 305-316
-
-
Krek, W.1
Nigg, E.A.2
-
12
-
-
0027433237
-
cdc2 kinase by the flavone L86-8275 in breast carcinoma cells. Correlation with decreased H1 kinase activity
-
cdc2 kinase by the flavone L86-8275 in breast carcinoma cells. Correlation with decreased H1 kinase activity. Biochem Pharmacol J 1993; 46: 1831-1840.
-
(1993)
Biochem. Pharmacol. J.
, vol.46
, pp. 1831-1840
-
-
Worland, P.J.1
Kaur, G.2
Stetler-Stevenson, M.3
-
13
-
-
0029665778
-
Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells
-
Carlson BA, Dubay MM, Sausville EA et al. Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. Cancer Res 1996; 56: 2973-2978.
-
(1996)
Cancer Res.
, vol.56
, pp. 2973-2978
-
-
Carlson, B.A.1
Dubay, M.M.2
Sausville, E.A.3
-
14
-
-
0032055497
-
Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity in vivo against human leukemia and lymphoma xenografts
-
Arguello F, Alexander M, Sterry JA et al. Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity in vivo against human leukemia and lymphoma xenografts. Blood 1998; 91: 2482-2490.
-
(1998)
Blood
, vol.91
, pp. 2482-2490
-
-
Arguello, F.1
Alexander, M.2
Sterry, J.A.3
-
15
-
-
0029904810
-
Flavopiridol: A cytotoxic flavone that induces cell death in noncycling A549 human lung carcinoma cells
-
Bible KC, Kaufmann SH. Flavopiridol: a cytotoxic flavone that induces cell death in noncycling A549 human lung carcinoma cells. Cancer Res 1996; 56: 4856-4861.
-
(1996)
Cancer Res.
, vol.56
, pp. 4856-4861
-
-
Bible, K.C.1
Kaufmann, S.H.2
-
16
-
-
0040932434
-
The novel cyclin-dependent kinase inhibitor flavopiridol downregulates Bcl-2 and induces growth arrest and apoptosis in chronic B-cell leukemia lines
-
Konig A, Schwartz GK, Mohammad RM et al. The novel cyclin-dependent kinase inhibitor flavopiridol downregulates Bcl-2 and induces growth arrest and apoptosis in chronic B-cell leukemia lines. Blood 1997; 90: 4307-4312.
-
(1997)
Blood
, vol.90
, pp. 4307-4312
-
-
Konig, A.1
Schwartz, G.K.2
Mohammad, R.M.3
-
17
-
-
0031963058
-
Early induction of apoptosis in hematopoietic cell lines after exposure to flavopiridol
-
Parker BW, Kaur G, Nieves-Neira W et al. Early induction of apoptosis in hematopoietic cell lines after exposure to flavopiridol. Blood 1998; 91: 458-465.
-
(1998)
Blood
, vol.91
, pp. 458-465
-
-
Parker, B.W.1
Kaur, G.2
Nieves-Neira, W.3
-
18
-
-
0032212885
-
Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis
-
Patel V, Senderowicz AM, Pinto D Jr et al. Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis. J Clin Invest 1998; 102: 1674-1681.
-
(1998)
J. Clin. Invest.
, vol.102
, pp. 1674-1681
-
-
Patel, V.1
Senderowicz, A.M.2
Pinto D., Jr.3
-
19
-
-
0002128714
-
In vitro evaluation of flavopiridol, a novel cell cycle inhibitor, in bladder cancer
-
Chien M, Astumian M, Liebowitz D et al. In vitro evaluation of flavopiridol, a novel cell cycle inhibitor, in bladder cancer. Cancer Chemother Pharmacol 1999; 44: 81-87.
-
(1999)
Cancer Chemother. Pharmacol.
, vol.44
, pp. 81-87
-
-
Chien, M.1
Astumian, M.2
Liebowitz, D.3
-
20
-
-
0029807115
-
Flavoriridol (L86 8275; NSC 649890), a new kinase inhibitor for tumor therapy
-
Sedlacek H, Czech J, Naik R et al. Flavoriridol (L86 8275; NSC 649890), a new kinase inhibitor for tumor therapy. Int J Oncol 1996; 9: 1143-1168.
-
(1996)
Int. J. Oncol.
, vol.9
, pp. 1143-1168
-
-
Sedlacek, H.1
Czech, J.2
Naik, R.3
-
21
-
-
0031670668
-
Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms
-
Senderowicz AM, Headlee D, Stinson SF et al. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. J Clin Oncol 1998; 16: 2986-2999.
-
(1998)
J. Clin. Oncol.
, vol.16
, pp. 2986-2999
-
-
Senderowicz, A.M.1
Headlee, D.2
Stinson, S.F.3
-
22
-
-
33845382806
-
Nonparametric estimation from incomplete observations
-
Kaplan EL. Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
-
(1958)
J. Am. Stat. Assoc.
, vol.53
, pp. 457-481
-
-
Kaplan, E.L.1
Meier, P.2
-
23
-
-
0030812207
-
Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: The importance of sequence of administration
-
Bible KC, Kaufmann SH. Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: the importance of sequence of administration. Cancer Res 1997; 57: 3375-3380.
-
(1997)
Cancer Res.
, vol.57
, pp. 3375-3380
-
-
Bible, K.C.1
Kaufmann, S.H.2
-
24
-
-
0030824869
-
Potentiation of apoptosis by flavopiridol in mitomycin-C treated gastric and breast cancer cells
-
Schwartz GK, Farsi K, Maslak P et al. Potentiation of apoptosis by flavopiridol in mitomycin-C treated gastric and breast cancer cells. Clin Cancer Res 1997; 3: 1467-1472.
-
(1997)
Clin. Cancer Res.
, vol.3
, pp. 1467-1472
-
-
Schwartz, G.K.1
Farsi, K.2
Maslak, P.3
-
25
-
-
0035679234
-
Augmentation of apoptosis and tumor regression by flavopiridol in the presence of CPT-11 in Hct116 colon cancer monolayers and xenografts
-
Motwani M, Jung C, Sirotnak FM et al. Augmentation of apoptosis and tumor regression by flavopiridol in the presence of CPT-11 in Hct116 colon cancer monolayers and xenografts. Clin Cancer Res 2001; 7: 4209-4219.
-
(2001)
Clin. Cancer Res.
, vol.7
, pp. 4209-4219
-
-
Motwani, M.1
Jung, C.2
Sirotnak, F.M.3
-
26
-
-
0005779480
-
A phase I/pharmacologic study of weekly sequential irinotecan (CPT) and flavopiridol (F)
-
Shah MA, Kortmansky J, Gotten M et al. A phase I/pharmacologic study of weekly sequential irinotecan (CPT) and flavopiridol (F). Proc Am Soc Clin Oncol 2002; 21: 373.
-
(2002)
Proc. Am. Soc. Clin. Oncol.
, vol.21
, pp. 373
-
-
Shah, M.A.1
Kortmansky, J.2
Gotten, M.3
|